October 29, 2015
Please join Fitch, Even, Tabin & Flannery LLP for a complimentary webinar, “Current and Emerging Trends in Patent Law: Cases to Know and Cases to Watch,” presented by Eric L. Broxterman and Joseph F. Marinelli. The webinar will take place on Thursday, October 29, 2015, at 9:00 am PDT / 10:00 am MDT / 11:00 am CDT / 12:00 noon EDT.
The patent landscape is constantly changing. Our webinar will help you stay informed on recent significant judicial developments in patent law, in both litigation and prosecution, and will provide a preview of Federal Circuit decisions on the horizon for the last quarter of 2015 and into 2016.
The webinar will cover these topics and more:
- Patent-eligible subject matter under Alice—DDR Holdings, LLC v. Hotels.com
- The Supreme Court’s new claim indefiniteness standard in Nautilus—Dow Chemical Co. v. NOVA Chemicals Corp.
- Expert apportionment method for proving damages by reasonable royalty—Summit 6 v. Samsung
- Standards for injunctive relief—Apple v. Samsung
- Good-faith belief of invalidity as a defense to inducement—Commil USA v. Cisco Systems
- Appellate standard for claim construction—TEVA Pharmaceuticals v. Sandoz
- Patent exhaustion based on foreign sales—Lexmark v. Impression
- Approval of biosimilars—Amgen v. Sandoz
Our speakers will be Fitch Even partners Eric L. Broxterman and Joseph F. Marinelli. Eric is a litigator with extensive trial experience in patent cases and a registered patent attorney who also counsels clients on patent prosecution, infringement/invalidity opinions, and IP transactional issues. Joe has a diverse intellectual property law practice covering all aspects of IP creation, management, enforcement, and licensing, with a particular emphasis on complex litigation.
IP Alert | Stock Ownership Leads to Vacatur of $2.75B District Court JudgmentAugust 8, 2022
On June 23, in Centripetal Networks v. Cisco Systems, the Federal Circuit vacated judgment of the district court because stock held by the judge's wife violated the recusal statute and was not harmless error. Read more
IP Alert | Rehearing Reverses Earlier Federal Circuit Decision Finding Silence Supported Negative Claim LimitationJuly 6, 2022
On June 21, in Novartis Pharmaceuticals Corporation v. Accord Healthcare, Inc., a reshuffled Federal Circuit panel reversed course on rehearing to find that a negative claim limitation was not supported by silence in the patent's specification. Read more